Literature DB >> 195035

The pharmacokinetics of d-tubocurarine in man with and without renal failure.

R D Miller, R S Matteo, L Z Benet, Y J Sohn.   

Abstract

Plasma and urine concentrations of d-tubocurarine (d-TC) were determined and twitch tension was monitored before and after the intravenous administration of d-TC, 0.5 mg/kg in patients anethetized with halothane and nitrous oxide with (N=5) and without (N=5) renal failure. Terminal half lives of d-TC of 231 and 330 minutes predicted from other studies for patients with and without renal function were consistent with plasma concentrations measured. In patients with normal renal function, 38% of unchanged d-TC was eliminated in urine in 25 hours as opposed to 13% in those patients with a newly transplanted kidney. However, we still conclude that a newly transplanted kidney can eliminate d-TC effectively since the kidney was inserted 3.5 hours after administration of d-TC. Absence of renal function significantly prolonged the duration of neuromuscular blockade but did not alter the plasma concentrations of d-TC required for neuromuscular blockade. Thus, prolonged neuromuscular blockade from d-TC in patients with renal failure is due to decreased elimination rate of the drug as a consequence of lack of renal function rather than increased sensitivity.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 195035

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  20 in total

Review 1.  Clinical pharmacokinetics of the newer neuromuscular blocking drugs.

Authors:  D P Atherton; J M Hunter
Journal:  Clin Pharmacokinet       Date:  1999-03       Impact factor: 6.447

Review 2.  Recent developments with muscles relaxants and their antagonists.

Authors:  R D Miller
Journal:  Can Anaesth Soc J       Date:  1979-03

Review 3.  Clinical pharmacokinetics of neuromuscular blocking drugs.

Authors:  S Agoston; R H Vandenbrom; J M Wierda
Journal:  Clin Pharmacokinet       Date:  1992-02       Impact factor: 6.447

4.  Influence of impaired renal function on the disposition of [14C]fazadinium in the anaesthetized greyhound [proceedings].

Authors:  D R Bevan; J Caldwell; J D'Souza; R L Smith
Journal:  Br J Pharmacol       Date:  1978-11       Impact factor: 8.739

Review 5.  Guide to drug dosage in renal failure.

Authors:  W M Bennett
Journal:  Clin Pharmacokinet       Date:  1988-11       Impact factor: 6.447

Review 6.  Influence of renal and hepatic function on pharmacodynamics and pharmacokinetics of non-depolarizing muscle relaxants.

Authors:  L H Booij
Journal:  Pharm Weekbl Sci       Date:  1987-04-24

7.  Pharmacokinetics/pharmacodynamics of furosemide in man: a review.

Authors:  L Z Benet
Journal:  J Pharmacokinet Biopharm       Date:  1979-02

8.  Clinical pharmacokinetics and pharmacodynamics of fazadinium in renal failure.

Authors:  D R Bevan; J D D'Souza; J M Rouse; J Caldwell; R L Smith
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

9.  Vecuronium in renal failure.

Authors:  D R Bevan; F Donati; H Gyasi; A Williams
Journal:  Can Anaesth Soc J       Date:  1984-09

Review 10.  Anesthesia and ventilation for the uremic child.

Authors:  S M Hall
Journal:  Pediatr Nephrol       Date:  1991-11       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.